Effect of Rosiglitazone on N-nitroso-N-methylurea-induced Mammary Tumors in Rat

• Autores: Bergoc, Rosa
• Año de publicación: 2020
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: ARTICULO; MEDICINA; CANCER DE MAMA; FARMACOLOGIA
• Institución: Fundación H. A. Barceló

Fil: Bergoc, Rosa. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
The objective of this study was to evaluate the in vivo antitumor action of rosiglitazone (Rosi) alone or in combination with tamoxifen (Tam) on experimental mammary tumors induced by N-nitroso-N-methylurea (NMU) in Sprague-Dawley rats. Animals bearing mammary tumors were treated with 0.06 mg/kg/day or 0.12 mg/kg/day of Rosi orally, 1 mg/kg/day of Tam sc, or with the combined treatment (Rosi+Tam). After 25 days of treatments, the following responses were observed: 45% of tumors were responsive to 0.06 mg/kg/day of Rosi treatment, while 55% of tumors under Tam treatment responded. Results of the combined Rosi+Tam treatment indicate that 75% of tumors were responsive. Similar results were obtained with 0.12 mg/kg/day of Rosi. Apoptosis, necrosis and glandular hypersecretion were observed in Rosi-treated tumors. In all cases, the combined Rosi+Tam treatment potentiates the antitumor effect of Tam alone. No side-effect was observed after treatment at any assayed dose.